Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Obviously, Dupixent in COPD has a broader label ... We have a significant burden of disease still in kids one year, two years and three years of age. And we believe that we have a step toward ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

by Caitlin Giddings and Wirecutter Staff Some of the best gifts for 1-year-olds are those that engage kids’ rapidly developing motor skills, sensory exploration, and boundless curiosity.

Ross takes pride in watching his children grow into “who they are going to be,” telling Miami Living Magazine in 2020 that he doesn’t "put a lot of pressure on my kids" because they are ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

“He is awesome and we are all so happy he is here! For the kids safety and privacy we won’t be posting any pictures- but he’s a really cute. We are feeling so blessed and grateful.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...